SARS-CoV-2-Specific Immune Responses in Patients With Postviral Syndrome After Suspected COVID-19.
Zachary S OrbanLavanya VisvabharathyGina S Perez GiraldoMillenia JimenezIgor J KoralnikPublished in: Neurology(R) neuroimmunology & neuroinflammation (2023)
had detectable anti-Nucleocapsid and one-half anti-Spike responses, highlighting the importance of multitargeted COVID-19 immunologic evaluation and the limitations of commercially available diagnostic tests. Despite their persistent symptoms, lack of COVID-19 diagnosis likely delayed clinical care in patients with PVS. Our data suggest that millions of Americans presenting with PVS resembling Neuro-PASC were indeed exposed to SARS-CoV-2 at the beginning of the pandemic, and they deserve the same access to care and inclusion in research studies as patients with NP with confirmed COVID-19 diagnosis.